Xeris Biopharma Holdings, Inc. (XERS)
Xeris is a biopharmaceutical company in Chicago that sells medicines for rare endocrine and neurological diseases. It last closed at $16.80 on Nov 17, up 0.60% on the day. The average 12-month price target from 5 analysts is $17.00 (+1.2% from the last close), with a high of $21.00 and a low of $12.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $746K, the largest $746K.
Key Stats
Last 12 monthsNot reported for this period.
From XERS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on XERS in the past 90 days. The average target is $17.00, with a high of $21.00 and a low of $12.00, compared with the last close of $16.80.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | Barclays | Target raised | Buy | $14 → $18 |
| Nov 6 | Oppenheimer | Reiterated | Buy | $21 |
| Nov 6 | Piper Sandler | Reiterated | Hold | $12 |
| Nov 6 | HC Wainwright & Co. | Maintained | Buy | $18 |
| Oct 6 | Barclays | Target raised | Buy | $12 → $14 |
Technical Analysis
The stock is 23% above its 20 day and 36% above its 50 day average. It is 53% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 86), overbought. The nearest support is the Pivot at $16.71, and the nearest resistance the 52 week high at $16.98.
| RSI (14) | 85.79 | Overbought above 70 | Overbought |
| MACD | 1.85 | Above its signal line | Bullish |
| Stochastic | 96.7 | Near the top of its range | Overbought |
| ADX (14) | 50.5 | Strong uptrend | |
| Williams %R | -2.7 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 97.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +62.3% | Change over 10 sessions | Bullish |
| ATR (14) | $0.72 | Typical daily range, 4.3% of price |
| RSI (14) | 86.12 | Overbought above 70 | Overbought |
| MACD | 1.99 | Above its signal line | Bullish |
| Stochastic | 98.6 | Near the top of its range | Overbought |
| ADX (14) | 38.2 | Trending up | |
| Williams %R | -1.9 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 245.1 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +125.5% | Change over 10 sessions | Bullish |
| ATR (14) | $1.24 | Typical daily range, 7.4% of price |
What happened before
See how XERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How XERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in XERS in the last 90 days.
Dark Pool
30DXERS Institutional Ownership
Full report →- ▲136 buying vs 98 selling
- ▲Held by funds +2.8 pts
- ▲Funds holding +9
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 250 | 241 | +3.7% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | 62.0% | 59.3% | +2.8 pts |
| New / increased | 33 / 103 | 34 / 106 | −2.9% |
| Reduced / sold out | 74 / 24 | 65 / 30 | +3.2% |
| Put/call ratio | 0.00 | 0.81 | −100.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XERS is in one of them and how their past XERS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered XERS in an article yet. Here's the latest on the wider market.
About Xeris Biopharma Holdings
Xeris is a biopharmaceutical company based in Chicago, Illinois, that develops and sells medicines for chronic endocrine and neurological diseases in the United States. Its marketed products include Recorlev for Cushing's syndrome, Gvoke, a glucagon treatment for severe low blood sugar, and Keveyis for primary periodic paralysis. Its customers include patients and the clinicians who treat them, and it is developing a weekly injectable form of levothyroxine for hypothyroidism.
- Headquarters
- Chicago, IL



